Enclomiphene vs Kisspeptin-10 (HPG Axis)
A side-by-side research comparison of Enclomiphene and Kisspeptin-10 (HPG Axis) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Enclomiphene | Kisspeptin-10 (HPG Axis) |
|---|---|---|
| Full name | Enclomiphene Citrate | Kisspeptin-10 (Metastin 45-54) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | Investigational drug | Research compound |
| Mechanism | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. | Binds KISS1R (GPR54) receptors on GnRH neurons in the hypothalamus, triggering pulsatile GnRH release. This cascades to LH/FSH secretion from the pituitary, maintaining the natural feedback loop. |
| Molecular weight | 598.09 Da | 1302.5 Da |
| Half-life | 10-14 hours | ~28 minutes (IV); ~4 hours (SubQ) |
| Bioavailability | ~50% oral | ~90% (subcutaneous) |
| Typical dose | 12.5-25 mg | 100-400 mcg |
| Frequency | Daily | 1-2x daily |
| Route | Oral capsule | Subcutaneous injection |
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
Kisspeptin-10 (HPG Axis) reported benefits
- Natural testosterone restoration
- Preserved HPG axis function
- Enhanced libido
- LH/FSH stimulation
- Potential fertility support
- No testicular suppression
Related comparisons
Research and educational reference only. Not medical advice.